SARS-CoV-2 Spike Protein Amplifies the Immunogenicity of Healthy Renal Epithelium in the Presence of Renal Cell Carcinoma.

SARS-CoV-2 Spike Protein Amplifies the Immunogenicity of Healthy Renal Epithelium in the Presence of Renal Cell Carcinoma.

Publication date: Dec 10, 2024

Renal cell carcinoma (RCC) is the most common form of kidney cancer, known for its immune evasion and resistance to chemotherapy. Evidence indicates that the SARS-CoV-2 virus may worsen outcomes for RCC patients, as well as patients with diminished renal function. Evidence suggests that the SARS-CoV-2 virus may exacerbate outcomes in RCC patients and those with impaired renal function. This study explored the unidirectional effects of RCC cells and the SARS-CoV-2 spike protein (S protein) on human renal proximal tubule epithelial cells (RPTECs) using a microphysiological approach. We co-cultured RCC cells (Caki-1) with RPTEC and exposed them to the SARS-CoV-2 S protein under dynamic 3D conditions. The impact on metabolic activity, gene expression, immune secretions, and S protein internalization was evaluated. The SARS-CoV-2 S protein was internalized by RPTEC but poorly interacted with RCC cells. RPTECs exposed to RCC cells and the S protein exhibited upregulated expression of genes involved in immunogenic pathways, particularly those related to antigen processing and presentation via the major histocompatibility complex I (MHCI). Additionally, increased TNF-α secretion suggested a pro-inflammatory response. Metabolic shifts toward glycolysis were observed in RCC co-culture, while the presence of the S protein led to minor changes. The presence of RCC cells amplified the immune-modulatory effects of the SARS-CoV-2 S protein on the renal epithelium, potentially exacerbating renal inflammation and fostering tumor-supportive conditions. These findings suggest that COVID-19 infections can impact renal function in the presence of kidney cancer.

Open Access PDF

Concepts Keywords
Cancer Carcinoma, Renal Cell
Covid Cell Line, Tumor
Healthy Coculture Techniques
Immunogenicity COVID-19
Kidney Epithelial Cells
Epithelium
Humans
Kidney
Kidney Neoplasms
Kidney Tubules, Proximal
renal cell carcinoma
renal proximal tubules
SARS-CoV-2
SARS-CoV-2
Spike Glycoprotein, Coronavirus
Spike Glycoprotein, Coronavirus
spike protein
spike protein, SARS-CoV-2

Semantics

Type Source Name
disease MESH Renal Cell Carcinoma
pathway KEGG Renal cell carcinoma
disease MESH kidney cancer
pathway KEGG Antigen processing and presentation
disease MESH histocompatibility
pathway REACTOME Glycolysis
disease MESH inflammation
disease MESH tumor
disease MESH COVID-19
disease MESH infections
disease IDO protein
drug DRUGBANK Coenzyme M
pathway REACTOME Immune System
disease MESH T cell exhaustion
disease MESH viral infection
disease MESH cytokine storms
disease MESH lymphopenia
disease MESH complications
disease MESH hypertension
disease MESH Acute kidney injury
disease MESH respiratory infections
disease MESH influenza
disease IDO host
disease IDO replication
pathway REACTOME Apoptosis
drug DRUGBANK Streptomycin
drug DRUGBANK Selenium
drug DRUGBANK Medical air
disease IDO assay
drug DRUGBANK Dextrose unspecified form
disease IDO biological process
drug DRUGBANK Oxygen
pathway KEGG Oxidative phosphorylation
drug DRUGBANK ATP
disease IDO production
pathway KEGG Metabolic pathways
drug DRUGBANK Cholesterol
disease IDO cell
pathway REACTOME Cholesterol biosynthesis
disease IDO immune response
pathway REACTOME Metabolism
drug DRUGBANK Isoxaflutole
pathway REACTOME Release
disease IDO process
disease MESH necrosis
disease IDO blood
drug DRUGBANK Gold
disease MESH Kidney Disease
drug DRUGBANK Angiotensin II
pathway REACTOME Translation
disease MESH Lung Inflammation
disease MESH Acute Respiratory Distress Syndrome
disease IDO infection
pathway REACTOME Fatty acid metabolism
disease MESH Melanoma
pathway KEGG Melanoma

Original Article

(Visited 1 times, 1 visits today)